{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T15:20:40Z","timestamp":1759936840587},"reference-count":0,"publisher":"International Union Against Tuberculosis and Lung Disease","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["int j tuberc lung dis"],"published-print":{"date-parts":[[2020,5,1]]},"abstract":"<jats:p><jats:bold>SETTING:<\/jats:bold> Prisons are known to have extremely high tuberculosis (TB) and multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB prevalence and poor treatment outcomes.<jats:bold>OBJECTIVE:<\/jats:bold> To examine the screening and M\/XDR-TB treatment with new TB drugs in prisons\n from the perspective of international ethical and legal requirements.<jats:bold>DESIGN:<\/jats:bold> WHO recommendations on TB screening in prisons and M\/XDR-TB treatment as well as the international human rights law on prisoners were analysed.<jats:bold>RESULTS:<\/jats:bold> Prisoners have a human right to access\n at least the same level of TB care as in their communities. Screening for TB in prisons, which may run contrary to a given individual's choice to be tested, may be justified by the positive obligation to prevent other prisoners from contracting a possibly deadly disease. Introduction of new\n TB drugs in prisons is necessary, ethically sound and should start in parallel with introduction in a civilian sector in strict compliance with the WHO recommendations.<jats:bold>CONCLUSION:<\/jats:bold> Access to screening for TB, as well as effective treatment according to WHO recommendations, must be\n ensured by countries on the basis of international human rights conventions.<\/jats:p>","DOI":"10.5588\/ijtld.17.0899","type":"journal-article","created":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T04:42:59Z","timestamp":1592541779000},"page":"57-60","source":"Crossref","is-referenced-by-count":1,"title":["Ethical issues in tuberculosis screening and the use of new drugs for prisoners"],"prefix":"10.5588","volume":"24","author":[{"given":"B. S.","family":"Elger","sequence":"first","affiliation":[{"name":"University Center of Legal Medicine of Geneva, University of Geneva, Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Mirzayev","sequence":"additional","affiliation":[{"name":"World Health Organization, Geneva, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Afandiyev","sequence":"additional","affiliation":[{"name":"Xazar Legal Service, Baku"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Gurbanova","sequence":"additional","affiliation":[{"name":"Ministry of Justice, Main Medical Department, Baku, Azerbaijan, Department of Pulmonary Medicine, Tartu Ulikool, Tartu, Estonia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3554","container-title":["The International Journal of Tuberculosis and Lung Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/iuatld\/ijtld\/2020\/00000024\/a00105s1\/art00011","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T04:30:53Z","timestamp":1592886653000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.5588\/ijtld.17.0899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,1]]},"references-count":0,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5,1]]}},"alternative-id":["1027-3719(20200501)24:5+L.57;1-"],"URL":"https:\/\/doi.org\/10.5588\/ijtld.17.0899","relation":{},"ISSN":["1027-3719"],"issn-type":[{"value":"1027-3719","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5,1]]}}}